Glucagon, a 29 amino acid peptide, that regulates glucose and amino acid metabolism, is a member of a large family of structurally-related peptides expressed in the gastro-intestinal and nervous systems. The goals are to gain an understanding of the biologic functions of this complex set of genes. During the past grant period we isolated and sequenced the cDNAs and genes encoding the rat pre-proglucagon, as well as two corresponding distinct angler fish cDNAs. The proglucagons are polyproteins that contain multiple glucagon-related peptides. The fish proglucagon encodes one and the rat two additional glucagon-like peptides. The processing of proglucagon differs markedly in pancreas vs. intestine resulting in the formation of three different glucagon-like peptide I's, glucagon-like peptide II, and an amidated intervening peptide. The glucagon-like peptide I(7-37) has potent insulinotropic actions and the other peptides derived from the proglucagon appear to be growth factors. We have developed clonal cell lines derived from rat islets that have different hormone-producing phenotypes and have initiated studies of the enhancer, silencer and metabolic-response elements involved in cell-specific and metabolic regulation of the gene. Cell-specific enhancer sequences and protein Kinase C-response elements appear to reside within one kilobase of the 5' flanking region of the gene.
Our aims are to: (1) isolate and structurally and functionally characterize the cis-acting DNA elements and the trans-acting DNA-binding proteins that govern cell-specific expression of the glucagon gene, (2) Characterize the antisera and radioimmunoassays for the GLP's and the structures of the GLP peptides, (3) determine the biologic functions of the glucagon-like peptides and (4) characterize the new glucagon-related peptides and genes expresed in the brain. These investigations have potential relevance to an understanding of cellular differentiation and the pathogenesis of diabetes mellitus.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Physiological Chemistry Study Section (PC)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Elahi, Dariush; Ruff, Dennis A; Carlson, Olga D et al. (2016) Does GLP-1 suppress its own basal secretion? Endocr Res 41:16-20
Liu, Z; Stanojevic, V; Avadhani, S et al. (2011) Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. Diabetologia 54:2067-76
Tomas, Eva; Habener, Joel F (2010) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21:59-67
Liu, Z; Habener, J F (2009) Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia 52:1589-98
Liu, Zhengyu; Habener, Joel F (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723-35
Elahi, Dariush; Egan, Josephine M; Shannon, Richard P et al. (2008) GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 16:1501-9
List, James F; He, Huile; Habener, Joel F (2006) Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept 134:149-57
Gragnoli, Claudia; Gragnoli, Claudio; Milord, Edrice et al. (2005) Linkage study of the glucagon receptor gene with type 2 diabetes mellitus in Italians. Metabolism 54:786-7
Lechner, Andreas; Nolan, Anna L; Blacken, Robyn A et al. (2005) Redifferentiation of insulin-secreting cells after in vitro expansion of adult human pancreatic islet tissue. Biochem Biophys Res Commun 327:581-8
Ogawa, Norihiko; List, James F; Habener, Joel F et al. (2004) Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700-5

Showing the most recent 10 out of 67 publications